

**Alaska Medicaid Pharmacy and Therapeutics Committee
Meeting September 18, 2020**

Frontier Building, 3601 C Street; Room 880/890

Please note, as a result of COVID-19 this meeting will be available via teleconference only.

Agenda

Public Call in: 1.800.315.6338. Access code **24251#**

1. **Call to Order – Chair** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment**

The Department’s methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where ***new information exists* and industry testimony will be taken. Classes shown in **Green** are classes with *no significant changes have been noted* and no industry testimony will be taken.

***New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.*

4. **Class review, discussion & vote.**

AK Treatment Class	Drug Class	Status
Gastrointestinal	Antiemetic-Antivertigo Agents	BLUE
	GI Motility & Irritable Bowel Syndrome, Chronic	RED
	Ulcerative Colitis	BLUE
	Cytokine & Cell-Adhesion Molecules (CAM) Antagonist – <i>GI indicated</i>	RED
Endocrine/ Metabolic	Antihyperuricemics	BLUE
	Progestins for Cachexia	GREEN
	Growth Hormone	GREEN
	Androgenic Agents, Topical	BLUE
	Bone Resorption Inhibitors	BLUE
	Hypoglycemics, SGLT2	BLUE
	Hypoglycemics, Metformin	BLUE
	Hypoglycemics, Alpha-Glucosidase	GREEN
	Hypoglycemics, Meglitinides	GREEN
	Hypoglycemics, Thiazolidinedione (TZD) and Combinations	GREEN
	Hypoglycemics, Dipeptidyl Peptidase-4 Inhib. (DPP-4) and Combinations	GREEN
	Hypoglycemics, Glucagon-like Peptide-1 (GLP-1) and Combinations	RED
	Rapid-Acting Insulins	RED
	Regular Insulins	GREEN
	Intermediate Insulins	GREEN
	Rapid/Intermediate-Acting Combination Insulins	BLUE
Regular/Intermediate-Acting Combination Insulins	GREEN	
Long-Acting Insulins	RED	
Phosphate Binders	GREEN	

Break as needed – 15 minutes

- 7. Review minutes** from **April 2020** meeting
- 8. Comments from Committee Members or Chair**
- 9. Adjourn**

Next Meeting Date: November 20, 2020